What You Should Know:
- Sanofi has entered into an agreement to acquire Vicebio Ltd (“Vicebio”), a privately held biotechnology company headquartered in London, UK. The acquisition expands Sanofi’s capabilities in vaccine design and development with Vicebio’s innovative ‘Molecular Clamp’ technology and brings an early-stage combination vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV) into its pipeline.
- The vaccine candidate complements
Read More
Life Sciences | News, Analysis, Insights - HIT Consultant
Unlocking the Power of Genomics in Clinical Trials: A Precision Medicine Data Imperative
As precision medicine continues to reshape the future of healthcare, clinical trials are evolving from one-size-fits-all studies into highly targeted investigations driven by genomics and biomarker-based insights. These trials not only test therapeutic efficacy but also help identify which patients are most likely to benefit, reducing trial-and-error in treatment and transforming hope into more predictable outcomes. With nearly half a million clinical trials underway globally, the potential to
Read More
Navigating Clinical Trials: Physicians Face Major Hurdles in Accessing Innovative Treatments
What You Should Know:
- myTomorrows, a global health technology company connecting patients and physicians with pre-approval treatments, published a new data report, "Searching for solutions: How physicians navigate trial access and technology."
- Based on a survey of 100 U.S.-based healthcare professionals, the report reveals that 61% of physicians find the process of identifying and accessing relevant clinical trials difficult, and 72% specifically find clinical trial
Read More
Define Ventures Report Reveals Pharma Accelerates AI Investment for Enterprise-Scale Deployment
What You Should Know:
- Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today released a report revealing how Big Pharma is accelerating investment in AI to counter rising cost pressure, regulatory shifts, and growing competitive urgency.
- The report is based on in-depth surveys and interviews with over 40 executives, including leaders from 16 of the top 20 pharma companies and major players like Amazon Web Services,
Read More
Patient-Centric Approaches in an Era of Multi-Indication Therapies
The life sciences industry has undergone a profound transformation over the past decade, evolving from a product-centric model to one that places patients at the center of its business strategy. This shift toward patient-centricity coincides with the rise of multi-indication therapies — treatments approved to address multiple conditions — to create a dynamic landscape that benefits both patients and life sciences companies alike.
The advent of patient-centricity
Patient-centricity requires
Read More
Century Health Brings AI Curated Datasets to Life Sciences Companies Through Datavant Connect and AWS Clean Rooms
What You Should Know:
- Century Health has announced a strategic partnership with Datavant Connect—powered by AWS Clean Rooms—to bring AI-curated, disease-specific datasets directly to pharmaceutical and life sciences companies through a secure, no-data-movement platform.
- By joining Datavant’s Lighthouse Partner Program, Century Health enables researchers to discover and assess high-quality, longitudinal clinical data in minutes—not months—without accessing or transferring sensitive
Read More
NVIDIA Introduces La-Proteina: A Breakthrough in Atomistic Protein Generation via Partially Latent Flow Matching
What You Should Know:
- NVIDIA Research, in collaboration with the University of Oxford and Mila – Québec AI Institute, has unveiled La-Proteina, a novel method for atomistic protein design.
- Published on arXiv on July 13, 2025, La-Proteina is designed to directly generate fully atomistic protein structures jointly with their underlying amino acid sequences, addressing a critical challenge in de novo protein design.
Optimizing Protein Design with Fixed-Dimensional Latent
Read More
Ryght Partners w/ Emory Cancer Institute for AI-powered Clinical Trials
What You Should Know:
- Ryght AI, a provider of real-time generative AI healthcare technology for clinical research, today announced that the prestigious Winship Cancer Institute of Emory University has joined its unique Ryght Research Network.
- The global network creates an AI digital twin of every research site worldwide, allowing distinguished academic institutions like Winship to leverage Ryght's AI platform and applications to revolutionize clinical trial processes and
Read More
Personalis Expands Tempus AI Collaboration to Include Colorectal Cancer
What You Should Know:
- Personalis, Inc. announced a significant expansion and extension of its strategic collaboration with Tempus AI, Inc. that adds colorectal cancer (CRC) as a new indication to their existing, exclusive commercialization partnership.
- Personalis and Tempus will now work together to bring the NeXT Personal® ultra-sensitive, tumor-informed minimal residual disease (MRD) test to market for detecting cancer recurrence across four key areas: breast, lung, and
Read More
Centivax Raises $45M to Commercialize First Universal Flu Vaccine
What You Should Know:
- Centivax, a biotech company developing durable, universal vaccines, today announced the close of a $45 million Series A led by Steve Jurvetson’s Future Ventures, with participation from NFX, BOLD Capital, Base4, Kendall Capital Partners, Amplify Bio, and existing investors.
- The new funding will advance Centivax’s lead universal flu vaccine candidate through CMC development and into a Phase I trial within eight months.
Centivax Accelerates Universal Vaccine
Read More
